Sign in
Enrolling by invitationPhase 2

Tests a low-dose combination pill for essential hypertension in adults

Tests a low-dose pill of candesartan, amlodipine and indapamide in adults with essential hypertension.

Key facts

Who runs it
Shin Poong Pharmaceutical Co. Ltd.
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
Status
Enrolling by invitation
Phase
Phase 2
People taking part
252 people, planned
Started
5 Dec 2024
Planned end
28 Feb 2026
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • SPC1001 Low
  • SPC5002
  • SPC5003
  • SPC5004
Record updated
14 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with essential hypertension (high blood pressure with no other known cause). It tests a three-drug combination pill against two-drug treatments for 8 weeks.

Age
19 to 75 years
Sex
Men and women
Disease stage
Essential hypertension. Blood pressure at the screening visit must meet set levels, which the record does not list.

Main reasons for not taking part

  • Blood pressure at screening and randomization of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg
  • Other conditions, which the record does not list

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria

Who cannot take part

  • Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 19 and 75 years old?

Where in South Korea

  • CHA Gangnam Medical Center, CHA UniversitySeoul, South KoreaEnrolling by invitation

About the trial

What the trial wants to find out

- Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to dual-component therapies of each ingredient for 8 weeks. Additionally, it seeks to confirm the contribution of each component at low doses.

Read full original descriptionShow less

- Inclusion Criteria: Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.

- Exclusion Criteria: Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.

- Methods: This study is a multicenter, randomized, double-blind, parallel-group, phase 2b clinical trial to evaluate the safety and efficacy of the investigational drug after 8 weeks of administration.

Screening assessments will be conducted within 4 weeks prior to randomization, and patients who meet the inclusion and exclusion criteria at the screening visit will be enrolled in the study after providing informed consent. These participants will undergo a 2-week run-in period during which they will take a placebo and participate in a lifestyle modification program.

The 4 groups in the trial

  • SPC1001 LowExisting treatment, for comparison

    low-dose combination therapy

  • SPC5002Existing treatment, for comparison

    low-dose combination therapy

    Treatment: SPC1001 Low and SPC5002

  • SPC5003Existing treatment, for comparison

    low-dose combination therapy

    Treatment: SPC1001 Low and SPC5003

  • SPC5004Existing treatment, for comparison

    low-dose combination therapy

    Treatment: SPC1001 Low and SPC5004

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Randomized, Double-blind, Parallel, Phase 2b Study to Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
Plain-language title
Tests a low-dose combination pill for essential hypertension in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07064525, who can take part
Record updated
14 July 2025